Abstract
Background Colorectal cancer (CRC) screening reduces CRC incidence and mortality. However, current screening methods are either hampered by invasiveness or suboptimal performance, limiting their effectiveness as primary screening methods. To aid in the development of a non-invasive screening test with improved sensitivity and specificity, we have initiated a prospective biomarker study (CRCbiome), nested within a large randomized CRC screening trial in Norway. We aim to develop a microbiome-based classification algorithm to identify advanced colorectal lesions in screening participants testing positive for an immunochemical fecal occult blood test (FIT). We will also examine interactions with host factors, diet, lifestyle and prescription drugs. The prospective nature of the study also enables the analysis of changes in the gut microbiome following the removal of precancerous lesions.
Methods The CRCbiome study recruits participants enrolled in the Bowel Cancer Screening in Norway (BCSN) study, a randomized trial initiated in 2012 comparing once-only sigmoidoscopy to repeated biennial FIT, where women and men aged 50-74 years at study entry are invited to participate. Since 2017, participants randomized to FIT screening with a positive test result have been invited to join the CRCbiome study. Self-reported diet, lifestyle and demographic data are collected prior to colonoscopy after the positive FIT-test (baseline). Screening data, including colonoscopy findings are obtained from the BCSN database. Fecal samples for gut microbiome analyses are collected both before and 2 and 12 months after colonoscopy. Samples are analyzed using metagenome sequencing, with taxonomy profiles, and gene and pathway content as primary measures. CRCbiome data will also be linked to national registries to obtain information on prescription histories and cancer relevant outcomes occurring during the 10 year follow-up period.
Discussion The CRCbiome study will increase our understanding of how the gut microbiome, in combination with lifestyle and environmental factors, influences the early stages of colorectal carcinogenesis. This knowledge will be crucial to develop microbiome- based screening tools for CRC. By evaluating biomarker performance in a screening setting, using samples from the target population, the generalizability of the findings to future screening cohorts is likely to be high.
Trial Registration ClinicalTrials.gov Identifier: NCT01538550
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01538550
Funding Statement
This project would not have been possible without funding from the Norwegian Cancer Society, the Research Council of Norway and the South Eastern Norway Regional Health Authority.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Both the BCSN trial, which the study recruits participants from, and the CRCbiome study have been approved by the Regional Committee for Medical Research Ethics in South East Norway (Approval no.: 2011/1272 and 63148, respectively). The BCSN is also registered at clinicaltrials.gov (Clinical Trial (NCT) no.: 01538550).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵æ Institute for Health and Society, University of Oslo, Oslo, Norway
Data Availability
Due to the principles and conditions set out in articles 6 (1) (e) and 9 (2) (j) of the General Data Protection Regulation (GDPR), research data generated in the CRCbiome study are not openly available. Further information on access to CRCbiome data can be found on the project web site: https://www.kreftregisteret.no/en/Research/Projects/microbiota-and-lifestyle-in-colorectal-cancer-screeing/
List of abbreviations
- AICR
- American Institute for Cancer Research
- ATC
- Anatomical Therapeutic Chemical
- AUC
- area under the curve
- BCA
- bovine serum albumin
- BCSN
- Bowel Cancer Screening in Norway
- Bp
- base pair
- CRC
- colorectal cancer
- CRN
- Cancer Registry of Norway
- CT
- computed tomography
- DDD
- defined daily doses
- DNA
- deoxyribonucleic acid
- DPIA
- Data Processing Impact Assessment
- FFQ
- food frequency questionnaire
- FIMM
- Institute for Molecular Medicine Finland
- FIT
- fecal immunochemical test
- FU
- follow-up
- gFOBT
- guaiac-based fecal occult blood test
- ICD
- International Classification of Diseases
- KBS
- Kostberegningssystem (“Dietary calculation system”)
- KEGG
- Kyoto Encyclopedia of Genes and Genomes
- LDQ
- lifestyle and demographic questionnaire
- NCT
- National Clinical Trial
- NorPD
- Norwegian Prescription Database
- NSAIDs
- non-steroid anti-inflammatory drugs
- PCR
- polymerase chain reaction
- PBS
- phosphate-buffered saline
- SCFA
- short chain fatty acid
- STROBE
- Strengthening the Reporting of Observational Studies in Epidemiology
- WCRF
- World Cancer Research Fund
- WHO
- World Health Organization
